In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a
new diagnostic tool for the imaging of neuroendocrine tumors. This application is based on …

More than 50 monoclonal antibodies (mAbs), including several antibody–drug conjugates,
are in advanced clinical development, forming an important part of the many molecularly …

In theranostics, radiolabeled compounds are used to determine a treatment strategy by
combining therapeutics and diagnostics in the same agent. Monoclonal antibodies (mAbs) …

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics …

Vascular endothelial growth factor (VEGF), released by tumor cells, is an important growth
factor in tumor angiogenesis. The humanized monoclonal antibody bevacizumab blocks …

Immune checkpoint inhibitors (ICIs), by reinvigorating CD8+ T cell mediated immunity, have
revolutionized cancer therapy. Yet, the systemic CD8+ T cell distribution, a potential …

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine
and 11C-5-Hydroxy-Tryptophan Page 1 Improved Staging of Patients With Carcinoid and Islet …

Vascular endothelial growth factor (VEGF)-A is overexpressed in most malignant and
premalignant breast lesions. VEGF-A can be visualized noninvasively with PET imaging and …

Context: Catecholamine excess is rare, but symptoms may be life threatening. Objective:
The objective of the study was to investigate the sensitivity of 6-[F-18] fluoro-l …

No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell
carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be …